The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma  

作　　者：Yan Song Juxiang Xiao Wentao Fang Ping Lu Qingxia Fan Yongqian Shu Jifeng Feng Shu Zhang Yi Ba Yang Zhao Ying Liu Chunmei Bai Yuxian Bai Yong Tang Jie He Jing Huang 

机构地区：[1]Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [2]Department of Medical Oncology,First Hospital of Xi’an Jiaotong University,Xi’an 710061,China [3]Department of Thoracic Surgery,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China [4]Department of Medical Oncology,First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China [5]Department of Oncology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China [6]Department of Oncology,The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China [7]Department of Medical Oncology,Jiangsu Cancer Hospital,Nanjing 210009,China [8]Department of Medical Oncology,Shandong Cancer Hospital,Jinan 250117,China [9]Department of Medical Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,China [10]Department of Biostatistics,School of Public Health,Nanjing Medical University,Nanjing 210029,China [11]Department of Medical Oncology,Henan Cancer Hospital,Zhengzhou 450008,China [12]Department of Oncology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100021,China [13]Department of Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150086,China [14]Department of Gastroenterology,Affiliated Tumor Hospital,Xinjiang Medical University,Urumqi 830011,China [15]Department of Thoracic Surgical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China

出　　处：《Cancer Biology & Medicine》2021年第2期562-568,共7页癌症生物学与医学（英文版）

基　　金：funded by the Chia Tai Tianqing Pharmaceutical Group Co,Ltd.

摘　　要：Objective:In this post-hoc analysis,we evaluated anlotinib treatment-induced hypertension as a potential predictive factor of efficacy in esophageal squamous cell carcinoma(ESCC)patients.Methods:A total of 109 patients enrolled in the anlotinib group in a phase 2 trial were included.The tumor response was assessed by computed tomography at week 3,week 6,and then every 6 weeks until progressive disease was observed.The primary endpoint of the study was progression free survival(PFS).The secondary endpoints included overall survival(OS)and objective response rate(ORR).Results:In all patients,the median PFS was 3.02 months[95%confidence interval(CI):2.63–3.65 months]and the OS was 6.11 months(95%CI:4.40–7.79 months).The ORR was 7.34%(95%CI:3.22%–13.95%).A total of 59(54%)patients were diagnosed with treatment-induced hypertension(Group A),and the remaining patients(n=50,46%)were in Group B.Baseline prognostic factors were similar between the 2 groups.Patients in Group A had a longer PFS and OS and higher ORR.When stratifying patients using a previously known history of hypertension,treatment-induced hypertension was a predictor only for patients without previous hypertension,who had longer PFS[hazard ratio(HR):0.40,95%CI:0.24–0.68]and OS(HR:0.37,95%CI:0.21–0.67).Conclusions:We showed,for the first time,a correlation between treatment-induced hypertension and better prognoses in recurrent or metastatic ESCC patients treated with anlotinib,without a previously known history of hypertension.Treatment-induced hypertension may be a simple and low cost predictor for anlotinib antitumor efficacy in these patients,which may also reflect the intended target inhibition.

关 键 词：Esophageal squamous cell carcinoma(ESCC) anlotinib treatment-induced hypertension prognostic predictor ANTIANGIOGENESIS 

分 类 号：R544.1[医药卫生—心血管疾病] R735.1[医药卫生—内科学]